Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Thomson Reuters StreetEvents
$75.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Medivir AB announces Simeprevir receives positive CHMP opinion for treatment of adults with chronic hepatitis C in the European Union


Friday, 21 Mar 2014 10:56am EDT 

Medivir AB:Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinion, recommending Marketing Authorisation in European Union.For use of simeprevir in combination with other medicinal products for treatment of chronic hepatitis C (CHC) in adult patients. 

Company Quote

119.25
-7.25 -5.73%
22 Aug 2014